Title: Idenix and Novartis Seek European Approval of Telbivudine for the Treatment of Patients With Chronic Hepatitis B
|
|
To print: Select File and then Print from your browser's menu Title: Idenix and Novartis Seek European Approval of Telbivudine for the Treatment of Patients With Chronic Hepatitis B |
|
"Idenix and Novartis Seek European Approval of Telbivudine for the Treatment of Patients With Chronic Hepatitis B" CAMBRIDGE, MA -- February 7, 2006 -- Idenix Pharmaceuticals, Inc. and Novartis announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) seeking marketing authorization for the 600 mg dose of telbivudine for the treatment of chronic hepatitis B. This MAA is the second in a series of submissions aimed at obtaining marketing approvals for telbivudine, an orally active, once-daily nucleoside analogue. A New Drug Application (NDA) was recently submitted with the United States Food and Drug Administration (FDA). Novartis expects to submit applications for marketing authorization in key Asian markets during the first quarter of 2006. "This MAA submission with the EMEA is another significant step in the development of telbivudine, a drug with the potential to improve the management of chronic hepatitis B, a disease with potentially fatal consequences that affects millions of people around the globe," said Jean-Pierre Sommadossi, chairman and chief executive officer of Idenix. "The submission of the MAA in Europe and the NDA in the U.S. within a month of each other demonstrates the strength of our ongoing collaboration with Novartis." The MAA submission is based primarily on one-year data from the GLOBE study, the largest registration trial for a chronic hepatitis B treatment. The GLOBE study is an ongoing, two-year, phase 3 clinical trial comparing telbivudine with a standard therapy, lamivudine, in the treatment of 1,367 adults with chronic hepatitis B from 112 clinical centers in 20 countries worldwide including (in Europe) the Czech Republic, France, Germany, Greece, Italy, Poland, Spain, Turkey, and the United Kingdom. GLOBE is the first international hepatitis B study to include clinical sites and patients in mainland China. Chronic hepatitis B is the most common serious liver infection in the world. It can cause liver failure, cirrhosis (scarring), liver cancer and death.1 It is caused by the hepatitis B virus (HBV), which infects the liver.[1 HBV is 50 to 100 times more infectious than HIV (the virus that causes AIDS).2 Chronic hepatitis B is the tenth leading cause of death worldwide.3 It affects approximately 350 million people worldwide and is responsible for up to 80 percent of the world's cases of primary liver cancer.4 Each year approximately 1.2 million people die worldwide from hepatitis B-related chronic liver disease.3 In Europe there are considerable regional differences in the prevalence of chronic hepatitis B, ranging from below 0.1% in Northwestern Europe to up to 8% in Eastern and Southern Europe.5 Despite the availability of treatments for chronic hepatitis B, significant unmet needs still exist, including the need for improved response rates, better-long-term efficacy, reduced rates of drug resistance, improved safety and tolerability, and more convenient dosing regimens. |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |